Janpix picks STAT inhibitors for blood cancers
How Janpix’s small molecules are specific for STAT3 and STAT5
Janpix is developing STAT3 and STAT5 inhibitors that could treat hematologic malignancies with greater durability and lower risk of side effects than other inhibitors of the JAK-STAT pathway.
Janpix Inc. in-licensed its family of small molecule scaffolds from the University of Toronto, where Janpix co-founder and CSO Patrick Gunning is a professor of chemistry.
In cancer, STAT proteins are phosphorylated and activated by JAKs and other kinases, causing STAT